慢性髓性白血病的脂质储存和治疗阻力:针对代谢脆弱性的新视角
Molly Tolland1,2, David M Ross1,2,3,4,5, Deborah White1,2
1Precision Cancer Medicine Theme, Blood Cancer Program, South Australian Health & Medical Research Institute, Adelaide 5000, Australia.
Cancers
|September 27, 2025
概括
改变的脂质储存可能导致慢性髓性白血病 (CML) 中对氨酸激酶抑制剂 (TKIs) 的耐药性. 准脂质代谢可能为耐性CML治疗的患者提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 癌症新陈代谢 癌症新陈代谢
- 血液学恶性瘤是什么
背景情况:
- 慢性髓性白血病 (CML) 治疗已取得进展,但对氨酸激酶抑制剂 (TKIs) 的耐药性仍然是一个挑战.
- 对于TKI抗性的分子基础通常是未知的,需要探索替代性抗性机制.
- 改变的脂质代谢越来越被认为是癌症耐药性的因素,包括CML.
研究的目的:
- 调查失调的脂质储存在CML中TKI耐药性的作用.
- 评估脂质储存作为克服CML中TKI耐药性的潜在治疗标.
- 确定针对TCI耐药性CML的新型辅助疗法.
主要方法:
- 对CML中脂质代谢的体外研究的综述.
- 对用脂向剂治疗的CML患者临床结果的分析.
- 对癌症抗药性脂质储存机制的当前文献的评估.
主要成果:
- 有证据表明,细胞内脂质储存可能起到保护作用,促进CML的耐药性.
- 直接或间接地准脂质储存途径显示出作为治疗策略的潜力.
- 慢性肌肉性ML作为研究对药物耐药性和疾病进展有助于代谢变化的模型.
结论:
- 不调节的脂质储存与慢性髓性白血病中TKI耐药性有关.
- 准脂质代谢为开发针对TCI耐药性CML的新疗法提供了一个有希望的途径.
- 对脂质代谢途径的进一步研究对于发现可操作的漏洞和改善CML治疗结果至关重要.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Lysosomal Hydrolases
4.4K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.4K


